A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma

Trial Profile

A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Olaratumab (Primary) ; Doxorubicin
  • Indications Leiomyosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Oct 2016 Results published in the Media Release
    • 19 Oct 2016 Results published in Eli Lilly and Company media release.
    • 19 Oct 2016 According to Eli Lilly and Company media release, the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery, based on data from the Phase 2 portion of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top